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ABSTRACT
Basic helix–loop–helix/Per–Arnt–Sim (bHLH/PAS)
transcription factors function broadly in develop-
ment, homeostasis and stress response. Active
bHLH/PAS heterodimers consist of a ubiquitous
signal-regulated subunit (e.g., hypoxia-inducible
factors, HIF-1a/2a/3a; the aryl hydrocarbon
receptor, AhR) or tissue-restricted subunit (e.g.,
NPAS1/3/4, Single Minded 1/2), paired with a
general partner protein, aryl hydrocarbon receptor
nuclear translocator (Arnt or Arnt2). We have
investigated regulation of the neuron-enriched Arnt
paralogue, Arnt2. We find high Arnt/Arnt2 ratios in
P19 embryonic carcinoma cells and ES cells are
dramatically reversed to high Arnt2/Arnt on
neuronal differentiation. mRNA half-lives of Arnt
and Arnt2 remain similar in both parent and
neuronal differentiated cells. The GC-rich Arnt2
promoter, while heavily methylated in Arnt only
expressing hepatoma cells, is methylation free in
P19 and ES cells, where it is bivalent with respect
to active H3K4me3 and repressive H3K27me3
histone marks. Typical of a ‘transcription poised’
developmental gene, H3K27me3 repressive marks
are removed from Arnt2 during neuronal
differentiation. Our data are consistent with a
switch to predominant Arnt2 expression in neurons
to allow specific functions of neuronal bHLH/PAS
factors and/or to avoid neuronal bHLH/PAS factors
from interfering with AhR/Arnt signalling.
INTRODUCTION
The mammalian basic helix–loop–helix/Per–Arnt–Sim
(bHLH/PAS) family of transcription factors consists of
19 structurally related proteins that are essential for a
plethora of biological processes, including oxygen homeo-
stasis, xenobiotic response, neurogenesis, appetite control
and circadian rhythm (1,2). Prototypical signal-regulated
members of this family include the aryl hydrocarbon
receptor (AhR) and hypoxia-inducible factor-alphas
(HIF-as), which exert their activities by heterodimerizing
with the common bHLH/PAS partner protein aryl
hydrocarbon receptor nuclear translocator (Arnt), to
form active DNA-binding complexes. In addition, Arnt
has been demonstrated to homodimerize to regulate
E-Box (CACGTG) harbouring adenovirus major late
promoter-driven reporter gene expression (3–5). Some
endogenous target genes of the homodimer have been
proposed (6).
In addition to Arnt, mammals also express an Arnt
paralogue known as Arnt2, which shares 80% amino acid
identity to Arnt across the N-terminal bHLH and PAS
regions (7), but is more divergent through the C-terminus.
Some intriguing differences exist between the two Arnt
paralogues. First of all, Arnt and Arnt2 show marked dis-
tinctions in their tissue-expression patterns. The Arnt tran-
scripts and proteins are almost ubiquitously expressed both
during fetal development and throughout adulthood,
although the expression level is low in certain parts of the
brain (8–10). In contrast, Arnt2 is much more tissue
restricted, being expressed predominately in the central
nervous system (CNS) and developing kidney (8–11).
Elevated Arnt2 expression has also been detected in the
tumour tissues of some breast cancer patients (12), where
increased Arnt2 mRNA was strongly correlated with
relapse-free survival and overall survival (12).
The reciprocal expression pattern of the two Arnt
paralogues in regions of the CNS and the correlation
between presence of Arnt2 and favourable outcome for
patients with mammary tumours led to the proposal that
there are unique functions of Arnt2 that cannot be per-
formed by Arnt. Several studies following targeted disrup-
tion of the Arnt2 gene in mouse and zebraﬁsh suggest that
adequate expression of Arnt2 is required for speciﬁc areas
of brain development (13–17). It has also been proposed
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that Arnt2 functions as the preferred binding partner of
neuronal bHLH/PAS proteins such as Single Minded 1
(Sim1) and Neuronal PAS 4 (NPAS4), owing to their gen-
erally overlapping expression patterns (17,18). However,
in transient transfection of cells with reporter genes, both
Arnt and Arnt2 are able to heterodimerize with Sim1 and
NPAS4 and regulate transcription (19,20 and unpublished
observations).
The second major difference between Arnt and Arnt2 is
the distinct phenotypes exhibited by Arnt- and Arnt2-
knockout (KO) mice. Arnt-null mice die in utero between
E9.5 and E10.5 owing to severe vascular defects (21,22),
similar to those seen in HIF-1-null mice (23,24). In
contrast, Arnt2-null mice die perinatally as a result of
impaired hypothalamus development (15,16), which
phenocopies the defects seen in Sim1-null mice (25). The
drastically different phenotypes between Arnt- and Arnt2-
null mice again point to non-overlapping functions of these
two proteins, especially during fetal development. On the
other hand, genotypes of progeny from crossed compound
heterozygous mutant Arnt+/ : Arnt2+/ mice did not
follow expected Mendelian inheritance, with offspring
null for either of Arnt or Arnt2 in combination with
being heterozygote for the other form of Arnt not surviving
beyond E8.5 (16). This early embryonic lethality suggests
that partial redundancy may also exist between Arnt and
Arnt2, at least at an early stage of fetal development.
Biochemical and reporter gene experiments indicate
that Arnt2, in similar fashion to Arnt, can form functional
heterodimers with AhR, HIF-as, Sim1 & 2 and NPAS4
in vitro and in cell cultures (7,17,18,26). However, partner-
ing of AhR with Arnt2 does not lead to expression of the
endogenous AhR target gene Cyp1a1, potentially due to
the presence of inhibitory proteins that weaken either
AhR/Arnt2 heterodimerization and/or transactivation
(10,27). Thus, the choice between partnering Arnt or
Arnt2 may be a mechanism for providing variable
outputs for bHLH/PAS proteins in vivo.
To better understand the differential roles of Arnt and
Arnt2 in development, we analysed the expression of Arnt
and Arnt2 in both embryonic carcinoma P19 cells and
mouse embryonic stem (ES) cells following retinoic acid
(RA)-induced neuronal differentiation. Both P19 and ES
cells express intermediate levels of endogenous Arnt2,
which could be induced several fold when differentiated
towards neuronal lineage. In contrast, robust levels of
Arnt rapidly decrease on differentiation, revealing a
switch between Arnt and Arnt2. We explore the mechan-
ism of this marked increase in Arnt2 expression and the
mechanism by which Arnt2 is repressed in non-neural
cells. Our data are consistent with current biological
data supporting speciﬁc neuronal functions of Arnt2
and/or a need to avoid interference with mitigated AhR/
Arnt function in neural tissue.
MATERIALS AND METHODS
Cell cultures
Murine embryonic carcinoma P19 cells and hepatoma
Hepa1c1c7 cells were routinely grown in minimum
essential medium alpha (MEM alpha) (Gibco/Cat No.
12571), supplemented with 10% fetal calf serum (FCS),
20mM L-glutamine, 100U/ml penicillin and 100 mg/ml
streptomycin, and cultured at 37C, with 5% CO2.
Mouse embryonic stem cells D3 (ES D3) were maintained
in high-glucose Dulbecco’s modiﬁed Eagle’s medium
(DMEM) (Gibco/Cat No. 11995), supplemented with
10% FCS, 20mM L-glutamine, 100U/ml penicillin,
100 mg/ml streptomycin, 1000U/ml leukemia inhibitory
factor (LIF) (Millipore/Cat. No. ESG1107) and 0.1mM
b-mercaptoethanol (Sigma/Cat No. 21985), and cultured
at 37C, with 5% CO2. Mouse V6.5 ES cells were main-
tained in ES D3 growth medium with irradiated (30
Grays) mouse embryonic ﬁbroblast (MEF) feeder layer.
Neuronal differentiation of P19 and ES cells
P19 cells were harvested and resuspended in P19 Induction
Medium (IM; MEM alpha, supplemented with 5% FCS,
20mM L-glutamine, 100 U/ml penicillin, 100 mg/ml
streptomycin), supplemented with 5 107 M RA.
1 106 cells in 10 ml P19 IM with RA were seeded onto
90-mm non-adherent petri dish (Techno Plas) and
cultured at 37C, with 5% CO2 to encourage embryoid
body (EB) formation. After 4 days, EBs were harvested
by gentle centrifugation and washed once in P19 IM
without RA. To dissociate EBs and form a single-cell sus-
pension, EBs were resuspended in 0.05% trypsin/EDTA in
PBS supplemented with 20 mg/ml DNase I (Sigma/Cat No.
DN-25) and incubated in 37C water bath for 10 min,
shaking every 2 min. P19 IM was added to EB/trypsin
mixture at 1:1 ratio to inactivate trypsin, and cells were
harvested by centrifugation. 2 106 cells were plated onto
a gelatine-coated 6-cm dish in P19 IM without RA. One
day after plating, P19 IM was changed to N2B27 medium
as previously described (28) with medium changed every 2
days.
For ES D3 cells, following washing and resuspension in
ES IM [high-glucose DMEM (Gibco/Cat No. 11995), sup-
plemented with 5% FCS, 20mM L-glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin], 1 106 cells were
seeded onto 90-mm non-adherent petri dish in ES IM
without RA for 4 days, followed by 1 107 M RA treat-
ment for 4 days, with medium changed every 2 days. EBs
were dissociated and plated onto poly-D-lysine-coated
dishes, and the neural-like cells were maintained as
described above.
For chromatin immunoprecipitation (ChIP) experi-
ments, V6.5 ES cells were subjected to direct neuronal
differentiation protocol as previously described (29).
Brieﬂy, cells were passaged at 1:5 ratio on to a feeder-
free gelatinized 10-cm dish. The following day, cells were
harvested and washed once with serum-free DMEM to
remove traces of LIF. Following resuspension in N2B27
(ES) medium (with 50 mg/ml bovine serum albumin frac-
tion V and 0.1mM b-mercaptoethanol), cells were
counted, and 1 106 cells were seeded per 10-cm dish in
N2B27 (ES) medium. One day after plating, medium was
changed completely. Afterwards, 50% of the medium was
refreshed every day.
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Muscle cell differentiation of P19 cells
Similar to P19 neuronal differentiation, muscular differ-
entiation of P19 cells was initiated by EB formation in P19
IM, supplemented with 1% DMSO. Following 4 days
culturing, EBs were resuspended in DMSO-free P19 IM,
re-seeded on 10-cm tissue culture dishes and cultured for
16 days, with medium change every 2 days.
Immunoblotting
Whole cell extracts were prepared as previously described
(30). Fifty microgram of cell lysate was separated on 10%
acrylamide SDS–PAGE gels and transferred onto nitro-
cellulose membranes using a wet transfer apparatus
(Bio-Rad). Proteins were detected with antibodies
against Arnt (MA-515, Afﬁnity BioReagents), Arnt2
(M-165, Santa Cruz Biotechnology), b-III-tubulin
(T2200, Sigma), MHC (MF20, Developmental Studies
Hybridoma Bank), a-tubulin (MCA78G, Serotec) and
horseradish peroxidase-conjugated secondary antibodies,
and visualized with Immobilon Western Chemilumin-
escent Substrate (Millipore). For densitometry plot,
band intensities were quantiﬁed by ImageJ software
(Rasband, W.S., ImageJ, U. S. National Institutes of
Health).
RNA extraction, cDNA synthesis and quantitative real
time PCR
Total RNA was extracted and reverse transcribed to
cDNA as previously described (30). Intron spanning
qRT-PCR primers were designed using online program
Primer3Plus (http://www.bioinformatics.nl/cgi-bin/
primer3plus/primer3plus.cgi). Sequences for all qRT-
PCR primers can be found at Supplementary Table S1.
Target gene expression was normalized against house-
keeping gene b-actin, which was largely unchanged
during the course of differentiation. All experiments
were performed in triplicates for three biological
replicates.
Immunoﬂuorescence
P19 cells were seeded onto coated round glass cover slips
in a four-well multiwell tray (Nunc) at deﬁned densities
(see RA-induced neuronal differentiation protocols
above). Cells were ﬁxed using 4% paraformaldehyde for
10 min. The following antibodies were used for protein
detection: mouse anti-Arnt (1A1, Origene), rabbit anti-
Arnt2 (M-165, Santa Cruz Biotechnology), rabbit anti-b-
III-tubulin (T2200, Sigma), mouse anti-b-III-tubulin
(T8578, Sigma). Following incubation with ﬂuorophore-
conjugated secondary antibodies (Invitrogen), slides were
mounted onto ProLong Gold with DAPI (P36935,
Invitrogen).
Bisulﬁte conversion of genomic DNA and sequencing
Bisulﬁte sequencing was performed as previously
described (31) with the following modiﬁcations. Brieﬂy,
genomic DNA was isolated using High Pure PCR
Template Preparation Kit (Roche). One microgram of
genomic DNA in 100 ml H2O was denatured at an
alkaline pH by adding 300 ml of 3M NaOH, and
incubated at 55C for 30min. Immediately 900ml of
freshly made bisulﬁte conversion solution [4.7M sodium
bisulﬁte (Sigma), 2.4mM hydroquinone (Sigma) and
361.5mM NaOH] was added, overlayed with 120 ml of
mineral oil (Bio-Rad) and incubated for a further 20 h at
55C. The bisulﬁte-treated DNA was then puriﬁed using
QIAquick Gel Extraction Kit (Qiagen), eluted in 2 40 ml
of H2O and alkaline desulfonated with 8 ml of 3M NaOH
for 15min at 37C. DNA was precipitated with 50 ml of 7.5
M ammonium acetate, 700 ml of 100% EtOH and 1 ml of
glycogen at 80C for 30min, followed by 1 700ml 75%
EtOH wash, and resuspended in 30 ml of H2O. Sequencing
primers for amplifying Arnt2 promoter were designed by
online program MethPrimer (http://www.urogene.org/
methprimer/index1.html), and were mArnt2_meth_F:
50 GAATGGTGTTTAATTTGGTTTTGA 30 and
mArnt2_meth_R: 50 AAAAAATCCCAAAAATTCTAC
CCTAT 30. Taq DNA polymerase (New England
Biolabs) was used for PCR with the following conditions:
5min at 95C, followed by 36 cycles of 30 s at 95C, 30 s at
60C and 15 s at 72C, and a ﬁnal extension for 5min at
72C. Ampliﬁed products were subcloned directly into
pGEM-T Easy vector (Promega) according to manufac-
turer’s instructions. For each cell line/condition, two bio-
logical replicates were analysed, and a total of 10
individual clones were selected and sequenced with M13
primers (50 GTAAAACGACGGCCAGT 30). Sequences
were combined and analysed using BiQ Analyzer
software (http://biq-analyzer.bioinf.mpi-inf.mpg.de/).
Clones that were likely to come from the same chromo-
some of the same cell or with <95% C to T conversion
rate of non-CpG cytosine residues were excluded from the
analysis.
mRNA stability studies
The half-lives of Arnt and Arnt2 mRNAs were determined
by Click-iT Nascent RNA Capture Kit (Life Techno-
logies) according to manufacturer’s instructions. Brieﬂy,
undifferentiated and 4-day RA-treated P19 cells were
labelled with 0.2mM ethynyl uridine (EU) and incubated
at 37C for 3 h. Cells were then allowed to recover in
EU-free medium for 0, 1, 2, 4, 6 h, respectively. Total
RNA was extracted (30), and 5mg of total RNA was
mixed with Click-iT reaction cocktail (25ml Click-iT EU
buffer, 4 ml 25mM CuSO4 and 2.5 ml 10mM Biotin azide).
Immediately, the reaction buffer additive 1 was added,
following by reaction buffer additive 2 exactly 3min
after adding of the ﬁrst additive, and the reaction was
carried out for 30min at room temperature. Following
incubation, the ‘clicked’ RNA was re-puriﬁed by
ammonium acetate precipitation (see above), and 0.5mg
of puriﬁed RNA was bound to 25 ml of streptavidin
magnetic beads with 80 units of RNAseOUT
Recombinant Ribonuclease Inhibitors (Life Technologies)
for 30min. Beads were then washed 5 300 ml of Click-iT
wash buffer 1, followed by 5 300 ml of wash buffer 2,
and resuspended in a ﬁnal volume of 25 ml wash buffer
2. The captured RNA was in-bead converted to cDNA
as per manufacturer’s instructions using SuperScript III
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Reverse Transcriptase (Life Technologies). Relative levels
of Arnt and Arnt2 mRNAs at each time point were
measured by qRT-PCR. All experiments were performed
in triplicates for three biological replicates.
Chromatin immunoprecipitation
ChIP was performed as previously described (32) using
2 mg of anti-trimethyl histone H3K4 (ab8580, Abcam) or
5 mg of anti-trimethyl histone H3K27 (07-449, Millipore)
antibodies, or 5 mg non-speciﬁc IgG as control (Upstate).
All real-time qPCR quantiﬁcations were performed in
triplicates for three biological replicates. Primer sequences
used in the ChIP experiments can be found in
Supplementary Table S1.
RESULTS
A switch in the ratio of Arnt/Arnt2 during neuronal
differentiation of P19 cells
A number of previous studies have shown that in contrast
to ubiquitously expressed Arnt, the paralogue Arnt2 has
expression restricted predominantly to the brain and de-
veloping kidneys (8,9,11). Consistent with this pattern,
N39, an immortalized mouse embryonic hypothalamus-
derived cell line (33), showed clear expression of Arnt2
mRNA, while conversely, hepatoma Hepa1c1c7 cells
expressed little or no Arnt2 (Supplementary Figure S1).
Furthermore, both embryonic carcinoma P19 cells and
ES cells expressed Arnt2 at comparable levels with that
found in the hypothalamic N39 cells (Supplementary
Figure S1).
Arnt2-null mice show perinatal lethality owing to de-
fective secretory neuron formation in the supraoptic
nuclei (SON) and paraventricular nuclei (PVN) of hypo-
thalamus (15), revealing a critical role for Arnt2 in certain
areas of brain development. To further characterize the
functions of Arnt2 during neurogenesis, we adapted a
widely used P19 differentiation system with kinetics rem-
iniscent of in vivo neuronal differentiation in murine
embryos (28), to monitor the change in Arnt and Arnt2
expression during neuronal differentiation (Figure 1A).
Both Arnt and Arnt2 transcripts can be clearly detected
in undifferentiated P19 cells (Supplementary Figure S1).
Given the relative ampliﬁcation efﬁciencies of these two
primer sets (93.1 and 95.7%, respectively), it was
estimated that the amount of Arnt transcripts in undiffer-
entiated P19 cells was approximately nine times higher
than that of Arnt2.
Differentiation of P19 cells led to rapid reduction of the
pluripotent marker gene Oct4, as well as induction of the
neuron progenitor cell (NPC) and postmitotic neuron
marker genes Sox1 and b-III-tubulin, respectively,
indicating a successful enrichment of neuronal cell popu-
lations in the culture (Supplementary Figure S2).
Intriguingly, neuronal differentiation of P19 cells also
led to marked increase in Arnt2 transcript levels, coinci-
dent with decreased Arnt mRNA expression (Figure 1A).
Thus, differentiation of P19 cells into neurons resulted in a
clear switch between the levels of Arnt and Arnt2
mRNAs, leading to predominant Arnt2 expression at
the later stage of P19 differentiation.
In addition to neuronal differentiation, P19 cells can
also be differentiated into cardiomyocytes and skeletal
myocytes of mesoderm linage in the presence of 1%
DMSO (34). To test whether the ratio of Arnt to Arnt2
was also altered by differentiation into an alternative
lineage, we used this protocol and demonstrated, as
expected, an increased expression of muscle precursor
and skeleton muscle cell markers MyoD and MHC
(myosin heavy chain), respectively (Supplementary
Figure S3). However, in stark contrast to neuronal differ-
entiation, muscular differentiation of P19 cells did not
alter the relative ratios of Arnt2 and Arnt at transcript
levels (Figure 1B), suggesting neuronal differentiation-spe-
ciﬁc mechanisms exist to invoke a switch in the ratio of
Arnt/Arnt2 expression.
The Arnt and Arnt2 protein levels were also examined
at different stages of P19 differentiation by immunoblot-
ting. Similar to that found for mRNAs, the Arnt/Arnt2
switch could also be detected at the protein level following
P19 neuronal differentiation, but was absent during
muscular differentiation (Figure 2). The increased expres-
sion of Arnt2 protein during neuronal differentiation
followed a similar kinetics as that of Arnt2 mRNA
(Figure 1A). In contrast, reduction of Arnt protein
appeared to be more rapid, with almost 10-fold reduction
after the ﬁrst 2 days of differentiation, while the Arnt
mRNA declined gradually during the course of neuronal
differentiation (Figure 1A).
A switch in the ratio of Arnt/Arnt2 during neuronal
differentiation of ES cells
To conﬁrm that increased Arnt2 and decreased Arnt
expression during neuronal differentiation is a general
phenomenon and not just peculiar to P19 cells, we
repeated our neuronal differentiation experiments with
ES cells. Neuronal differentiation of ES cells led to a
marked reduction of Oct4 and increased expression of
Sox1 and b-III-tubulin (Supplementary Figure S4), very
similar to that seen in P19 differentiation, demonstrating a
successful enrichment of NPC and neuron populations in
the culture. This was also supported by microscopic
analysis showing extensive neurite formation in
differentiated ES cultures (Supplementary Figure S4).
Furthermore, consistent with P19 neuronal differenti-
ation, differentiation of ES cells led to increased Arnt2
and decreased Arnt expression at both mRNA and
protein levels (Figure 3). Thus, the trend of an Arnt/
Arnt2 switch was consistent in both P19 and ES differen-
tiation models.
Arnt2 is predominantly expressed in the neuronal cell
population in differentiated P19 cells
Although mRNA and protein expression analyses
demonstrated a switch in the ratio of Arnt to Arnt2
levels during RA-induced neuronal differentiation, they
did not show that the increase in Arnt2 levels occurred
speciﬁcally in neurons. We therefore performed immuno-
cytochemistry to determine whether Arnt2 was
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Figure 1. Neuronal differentiation of P19 cells increased expression of Arnt2 mRNA concomitant with decreased expression of Arnt mRNA.
(A) Scheduled protocol for neuronal differentiation of P19 cells via growth of EBs in the presence of 500 nM RA, followed by seeding and incubation
in neurobasal N2B27 media. Differentiation of P19 cells into NPCs and neurons resulted in a switch between the Arnt and Arnt2 transcript ratios as
assayed by real time qRT-PCR. (B) Scheduled protocol for P19 muscle cell differentiation by the addition of 1% DMSO. In contrast to neuronal
differentiation, muscle cell differentiation did not alter the ratio of Arnt2 versus Arnt transcripts. All data are mean±SEM, n=3.
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co-localized with the neuron marker b-III-tubulin.
Consistent with mRNA and protein expression data in
untreated P19 cells, both Arnt and Arnt2 were present
in all non-differentiated P19 cells (Figure 4A). Upon dif-
ferentiation towards neuronal lineages, Arnt expression is
still observed in b-III-tubulin-negative and -positive cells.
b-III-tubulin-negative cells, however, express barely de-
tectable levels of Arnt2 compared with relatively high
levels in b-III-tubulin-positive cells (Figure 4B). We
counted immunostained cells from two independent dif-
ferentiation experiments and found that the b-III-tubulin-
positive cell population consistently contained a higher
percentage of Arnt2-positive cells (average of
70.2±1.4%) compared with the b-III-tubulin-negative
cell population (average of 9.3±17.8%) (Figure 4C).
This indicates that, similar to the in vivo expression
pattern (15), Arnt2 is enriched in cells of neuronal
lineage. Put together, these observations demonstrate
that the switch in ratio is due to enrichment of the
neuronal cell population, which expresses Arnt2 at high
levels.
Increased expression of Arnt2 in differentiated P19 cells is
a result of increased Arnt2 transcription
During neuronal differentiation, both P19 and ES cells
exhibit a several fold increase in Arnt2 transcripts levels
(Figures 1 and 3). However, whether this increase is the
result of increased Arnt2 gene transcription or whether it
is due to enhanced mRNA stability is unknown. To
distinguish between these two possibilities, we used an
RNA pulse labelling strategy followed by puriﬁcation and
quantitative PCR to measure the half-lives of Arnt and
Arnt2 transcripts in both undifferentiated and 4-day
RA-treated P19 cells (Figure 5). The half-lives of Arnt
and Arnt2 mRNAs were relatively constant in both undif-
ferentiated and differentiated cells. In addition, the Arnt and
Arnt2 mRNAs displayed very similar half-lives, measured
to be 2.5 h in P19 cells, although the Arnt2 transcript may
Figure 2. Neuronal differentiation of P19 cells increased Arnt2 and decreased Arnt protein expression. (A) Immunoblotting showing increased Arnt2
and decreased Arnt expression during neuronal differentiation of P19 cells as outlined in Figure 1A. (B) Immunoblotting of Arnt2 and Arnt proteins
during muscle cell differentiation of P19 cells as outlined in Figure 1B. Relative levels of Arnt2 versus Arnt were largely unchanged during muscle cell
differentiation. (C and D) Densitometry plots showing the log ratios of Arnt2 versus Arnt protein levels using the data presented in parts A and B,
respectively. Data shown are representative from two independent experiments.
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have a slightly longer half-life than that of Arnt. These
results indicate that increased Arnt2 expression during
differentiation results from increased Arnt2 gene transcrip-
tion, with only a minor component, if any, due to increased
Arnt2 mRNA stability.
Methylation status of the Arnt2 promoter in neuronal and
non-neuronal cells
In an effort to further characterize the mechanism under-
lying enhanced Arnt2 expression during neuronal
differentiation, transcription factor-binding site analysis
on the proximal promoters of human, mouse and rat
Arnt2 loci was performed. From this analysis, binding
sites for transcriptional repressor protein REST (RE1
silencing transcription factor, also known as NRSF or
neuron-restrictive silencer factor) were found to be over-
represented at the Arnt2 promoter of all three species.
In addition, REST was shown to be recruited to the
human Arnt2 promoter in a genome wide ChIP-seq
study (35). As REST is a negative master regulator of
neurogenesis that represses expression of neuronal genes
Figure 3. An Arnt/Arnt2 switch during neuronal differentiation of ES cells. (A) Scheduled protocol for neuronal differentiation of ES cells via
formation of EBs and treatment with 500 nM RA, followed by seeding and incubation in neurobasal N2B27 media. (B and C) Real time qRT-PCR
results showing increased Arnt2 and decreased Arnt expression during ES cell neuronal differentiation. Data are mean±SEM, n=3. (D) log ratios
of Arnt2 versus Arnt derived from parts (B) and (C). (E) Immunoblotting showing increased Arnt2 and decreased Arnt protein expression during
neuronal differentiation of ES cells. Data are representative from two independent experiments. (F) Relative band intensities for Arnt and Arnt2
proteins in part (E) were determined by densitometry and plotted as log ratio of Arnt2 versus Arnt.
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in non-neuronal cells by recruiting histone deacetylase
(HDAC) (36,37), we thought it logical to test the role
of REST in regulating Arnt2 gene expression. Of note, a
recent study in our laboratory showed that neuron-re-
stricted expression of NPAS4, another bHLH/PAS
protein, is REST dependent (D. Bersten, manuscript in
preparation).
To test the role of REST in regulating Arnt2 expression,
we transiently transfected P19 cells with a dominant
negative mutant of REST, or treated cells with the
Figure 4. Arnt2 is predominantly expressed in neuronal cells following differentiation. (A) Arnt and Arnt2 proteins were detected in the nuclei of
undifferentiated P19 cells by immunocytochemistry. (B) After an 8-day differentiation protocol as outlined in Figure 1A, Arnt was observed in both
b-III-tubulin-positive (arrowhead) and -negative (arrow) cells, while Arnt2 was strong in b-III-tubulin-positive cells but barely detectable in b-III-
tubulin-negative cells. Nuclei are visualized by blue DAPI staining. Data are representative of two independent experiments. (C) There are more
Arnt2-positive cells within a population of randomly selected b-III-tubulin-positive cells than within a population of randomly selected b-III-tubulin-
negative cells. Approximately 70 cells were counted for each b-III-tubulin status group per experiment. Data are mean±SD, n=2.
Figure 5. Neuronal differentiation of P19 cells has little effect on the stability of Arnt or Arnt2 mRNAs. Half-lives of Arnt and Arnt2 mRNAs in
undifferentiated (A) and 4-day RA-treated (B) P19 cells were measured by Click-iT Nascent RNA Capture Kit as described in Materials and
Methods. The half-lives of Arnt and Arnt2 mRNAs were respectively calculated to be 2.3±0.6 and 2.9±0.1 h in undifferentiated P19 cells, and
2.3±0.4 and 2.6±0.2 h in RA-induced P19 cells. Data are mean±SEM, n=3.
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HDAC inhibitor trichostatin A, and measured the expres-
sion level of Arnt2 mRNA following each treatment.
Unexpectedly, neither of these treatments increased the
expression level of Arnt2 (data not shown), consistent
with a REST-independent pathway of Arnt2 regulation
in differentiated P19 cells.
Inspection of the mouse Arnt2 locus also showed that
the Arnt2 promoter is highly GC rich and contains a CpG
island (Figure 6A) that is highly conserved among
mammals (Supplementary Figure S5). As global DNA
demethylation has been reported to be a permanent
feature of P19 cells during neuronal differentiation (38),
it is plausible that the change in expression of Arnt2 is a
result of decreased methylation status of the Arnt2
promoter during neuronal differentiation. To test this
hypothesis, genomic DNA was extracted from undifferen-
tiated and RA-treated (2- and 4-day) P19 cells and sub-
jected to bisulﬁte sequencing analysis. Unexpectedly,
no DNA methylation was found at the promoter region
of the Arnt2 locus in either undifferentiated or
differentiated P19 cells, suggesting that the increased ex-
pression of Arnt2 in differentiated P19 cells is not a result
of attenuated DNA methylation (Figure 6B). Conversely,
the Arnt2 promoter in hepatoma Hepa1c1c7 cells, which
do not express Arnt2, was highly methylated (Figure 6B).
Thus, although the methylation status of the Arnt2
promoter did not contribute to the regulation of Arnt2
gene in P19 cells, hypermethylation of Arnt2 promoter is
likely to occur in other tissue types where Arnt2 is not
detectable, which is probably the mechanism for silencing
the Arnt2 gene in tissues such as liver (Supplementary
Figure S1).
The Arnt2 promoter displays the epigenetic hallmarks of a
lineage-speciﬁc gene
As the Arnt2 promoter is not methylated in undifferenti-
ated P19 cells, we hypothesized that epigenetic modiﬁca-
tions might confer a level of repression that could be
reversed in neuronal cells on differentiation. We therefore
performed ChIP experiments to test for the presence of
trimethylated histone 3 lysine 27 (H3K27me3), a
common repressive marker, and H3K4me3, a common
active marker, in Arnt and Arnt2 promoter regions.
As expected, the Arnt promoter did not contain the repres-
sive mark in undifferentiated ES cells, neuronal
differentiated ES cells or Hepa1c1c7 cells, but was
Figure 6. Mapping the DNA methylation status of the Arnt2 promoter in P19 and Hepa1c1c7 cells. (A) CpG island prediction in the murine Arnt2
promoter using MethPrimer software. Criteria used for prediction were island size >100 bp, GC percentage >30% and observed/expected CpG ratio
>0.6. A single CpG island of 851 bp was identiﬁed, which spread across the transcriptional start site of the murine Arnt2 gene. (B) Bisulﬁte
sequencing revealed the Arnt2 promoter was not methylated in either undifferentiated P19 cells (2d -RA) or 2 day and 4 day differentiated (i.e.
2d and 4d+RA treated) P19 cells, but was hypermethylated in hepatoma Hepa1c1c7 cells. The black circles indicate methylated CpG sites, and white
circles indicate unmethylated CpG sites. PCR fragment analysed indicated by F and R boxes in (A).
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marked with H3K4me3 in all three of these cell popula-
tions (Figure 7A). These observations were consistent with
the ubiquitous expression of Arnt across tissue types.
The Arnt2 promoter in undifferentiated ES cells con-
tained both H3K27me3 and H3K4me3, two opposing
epigenetic markers (Figure 7B). This phenomenon, previ-
ously described as a bivalent marker, has been typically
found in the promoters of genes that are poised for
expression during early development (39–41). It has been
proposed that H3K27me3 and the associated polycomb
repressor complex tends to override the active marker
H3K4me3 at bivalent promoters (39,41), consistent with
our ﬁnding of the high Arnt/Arnt2 ratio in untreated ES
cells.
On differentiation, bivalently marked genes can be acti-
vated or repressed in a tissue-speciﬁc manner via conver-
sion into monovalency (41). In keeping with this model,
we found a decrease in the presence of H3K27me3 at the
Arnt2 promoter following 7-day neuronal differentiation
of ES cells (Figure 7B), which correlated with the increase
in Arnt2 expression. Notably, in conﬁrmation of our
results, global ChIP-sequencing analyses of H3K4me3
and H3K27me3-marked chromatin reported that the
Arnt2 promoter contained both of these modiﬁcations in
undifferentiated ES cells, but only H3K4me3 in neural
progenitor cells (41).
In Hepa1c1c7, we found the Arnt2 promoter contained
no H3K4me3 and some H3K27me3 (Figure 7B). This is
again consistent with the lack of Arnt2 expression in
non-neuronal differentiated cells.
In summary, Arnt2 expression in undifferentiated ES
cells was dampened through bivalent epigenetic modiﬁca-
tion, and loss of the repressive marker on neuronal differ-
entiation led to a substantial increase in expression. Arnt2
was fully repressed in non-neuronal Hepa1c1c7 cells,
through hypermethylation of its promoter and persistence
of the H3K27me3-repressive epigenetic modiﬁcation.
Ubiquitous Arnt expression across various cell types was
in agreement with presence of the active H3K4me3
epigenetic marker and absence of repressive H3K27me3
in its promoter.
DISCUSSION
In this study, we provide evidence that neuronal differen-
tiation of P19 and ES cells alters the expression levels of
Arnt and Arnt2, leading to increased Arnt2 and decreased
Arnt at both mRNA and protein levels (Figures 1–4).
Increased Arnt2 expression has also been reported in
NGF (nerve growth factor)-treated rat pheochromocy-
toma PC12 cells, a rat model for neuronal differentiation
(42), providing a third example of this phenomenon and
demonstrating that the mode of Arnt/Arnt2 switch follow-
ing neuronal differentiation is likely to be general and in-
dependent of cell lines studied. Furthermore, the
expression pattern of Arnt/Arnt2 in our in vitro models
also matches well with the in vivo expression pattern of
these two proteins (8–11).
Alternation of Arnt/Arnt2 expression following neuronal
differentiation is a distinctly regulated process, as muscular
differentiation of P19 cells did not reproduce this phenom-
enon (Figures 1 and 2). It appears that at least two inde-
pendent mechanisms exist in regulating Arnt2 expression
in non-neuronal cells. First of all, the expression of Arnt2
in non-neuronal non-pluripotent cells can be silenced by
DNA hypermethylation, resulting in a complete repression
of Arnt2 gene expression. This was demonstrated by
studies in hepatoma Hepa1c1c7 cells, where the expression
of Arnt2 was fully repressed (Figure 6 and Supplementary
Figure S1). In addition, expression of Arnt2 in pluripotent
ES and P19 cells could also be subject to polycomb-
dependent regulation, which only partially represses
Arnt2 expression. In this scenario, repression can be
readily reversed by alteration of polycomb-associated epi-
genetic marks such as H3K27me3. Alternatively, a bivalent
Arnt2 promoter may receive signals to remove positive epi-
genetic marks such as H3K4me3 during differentiation to
non-neural cell types. It will now be interesting to test this
model by tracing epigenetic marks on the Arnt2 promoter
while subjecting ES cells to some of the emerging in vitro
Figure 7. Active and repressive histone methylation marks on the Arnt
and Arnt2 promoters in undifferentiated ES cells, 7-day neuronal
differentiated ES cells and Hepa1c1c7 cells. ChIP-qPCR data showed
the Arnt promoter in all three cell types to contain the active marker
H3K4me3, but no repressive marker H3K27me3 (A). The Arnt2
promoter was bivalently marked in undifferentiated and differentiated
ES cells, but the repressive marker decreased in differentiated cells.
Only the repressive marker was detected in Hepa1c1c7 cells (B). Data
are mean±SEM, n=3.
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differentiation protocols shown capable of providing a
range of cell lineages.
In attempts to understand the mechanism behind
reduced Arnt expression, we examined the effects of P19
neuronal differentiation on miR-107 expression, as this
was recently shown to reduce Arnt levels in response to
p53 activity in human colon cancer specimens (43), and
analysis of mouse embryos suggest that miR-107 is
expressed predominately in the brain and neural tube,
but not in the other developing organs (44). However,
qRT-PCR analysis showed only minor increases in
the expression levels of both pre-miR-107 and the miR-
107-harbouring Pank1 gene at different stages of P19
neuronal differentiation (data not shown), making it
unlikely miR-107 exerts a major inﬂuence on attenuated
Arnt expression. As Arnt protein loss is more rapid
than the reduction in Arnt mRNA levels, we suspect
that Arnt protein loss most likely results from a signal-
induced ubiquitylation/proteasome pathway or protease
activity.
Although it is important to explore the mechanism of
the switch between Arnt species during neuronal differen-
tiation, the question of why this switch occurs now needs
to be addressed. We have observed that as Arnt2 becomes
expressed during the differentiation process, the neural
bHLH/PAS transcription factors Sim1 and NPAS4 also
begin to be expressed (Hao, unpublished results). The data
imply that a switch may be needed for function of Sim1
and/or NPAS4, or perhaps other neuronal transcription
factors such as NPAS1 and NPAS3. Mouse knock out
studies have revealed Arnt2 to be the in vivo partner of
Sim1 in the hypothalamus (17), and Arnt2 has also been
reported to be the predominant partner of NPAS4 in the
brain (19). Ooe et al. suggest that NPAS4 has higher
afﬁnity for Arnt2 than Arnt, consistent with the idea
that Arnt2 may be needed for neuronal functions unable
to be performed by Arnt. Interestingly, a reciprocal
scenario exists for the AhR, which activates its classic en-
dogenous target gene Cyp1a1 when co-expressed with
Arnt, but not with Arnt2 (10,27). Thus, the species of
Arnt partner protein may have a previously unappreciated
role in deﬁning output of varying bHLH/PAS complexes.
Although in vitro experiments and transfected reporter
gene assays have generally failed to detect speciﬁcity
between Arnt and Arnt2 when paired with a range of
bHLH/PAS proteins, activities on endogenous target
genes, which are largely ill-deﬁned for Sim1 and NPAS4,
have yet to be analysed.
Ancestral genes of the AhR play roles in neuron devel-
opment in both Caenorhabditis elegans (45) and
Drosophila (46), both of which express a single equivalent
of Arnt. Mammalian AhR is ubiquitous and has recently
been reported to function in proliferation, survival and
differentiation of neurons in the dentate gyrus of the
hippocampus (47), a region of the brain which shows
high NPAS4 expression (18). A possible reason for the
altered ratio of Arnt/Arnt2 expression may be to allow
AhR and NPAS4 to function in separate pathways
without competing for a common partner factor, thus
avoiding cross interference. Analysis of cell extracts has
revealed the AhR to have a higher afﬁnity for Arnt than
Arnt2 within the cell (10,27,48); thus, increasing Arnt2
expression in neurons could provide a second Arnt
species with dampened interaction with the AhR,
clearing the way for dimerization with NPAS4 in the
hippocampus, or likewise Sim1 in the hypothalamus,
or perhaps other bHLH/PAS proteins elsewhere in the
brain. In higher organisms, the extra form of Arnt may
well have arisen to allow increased complexity and
specialization of neuronal bHLH/PAS factors. In
keeping with this model, BMAL (Brain and Muscle
ARNT-like) is a further bHLH/PAS protein with
homology to Arnt in the bHLH and PAS domains, yet
in vivo BMAL seems to exclusively dimerize with the cir-
cadian rhythm factor, Clock (1). Clock/BMAL complexes
drive the circadian pacemaker in the suprachiasmatic
nucleus of the hypothalamus, providing a prototypical
example of speciﬁc output from an Arnt-like protein.
In conclusion, although it is apparent that both Arnt
and Arnt2 have the capacity to interact with a wide
range of bHLH/PAS proteins (e.g. Sim1, Sim2, NPAS4,
HIF-1a, HIF-2a, AhR), speciﬁc complexes may be
favoured in a given cell type, determined by factors such
as the relative expression level of each Arnt together with
possible cell-speciﬁc modifying factors or signal-induced
posttranslational modiﬁcations.
Finally, the AhR has recently been shown to function
as a ubiquitin ligase for certain nuclear receptors, such as
the Estrogen Receptor (ER), with Arnt being found in
the AhR ubiquitin ligase complex (49). An unexplored
alternative possibility is that decreased Arnt in neurons
may be needed to dampen detrimental AhR-induced
ubiquitylation, and associated proteasomal degradation,
of proteins important for neuron function, e.g. the ER.
A switch to predominantly Arnt2 in neurons would thus
allow neuronal bHLH/PAS factors to perform essential
functions free of possible side effects that may occur in
the presence of high levels of Arnt.
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